Options
胸水衍生內生性 DCTN1–ALK 融合肺腺癌模型之建立
Date Issued
2026
Author(s)
白欣諭
BAI, SINYU
Advisor
張基晟
Abstract
肺癌長期位居全球與台灣癌症死因之首,非小細胞肺癌(non-small cell lung cancer, NSCLC)以肺腺癌為主要病理類型。雖已知EGFR、KRAS突變及ALK基因重排為關鍵致癌驅動基因與分子標的,多世代 ALK 酪胺酸激酶抑制劑(tyrosine kinase inhibitors, ALK-TKIs)已顯著改善病人預後,然而不同融合蛋白基因(如EML4、DCTN1)形塑獨特的蛋白質空間構型並影響藥物敏感性。本研究旨在自惡性胸腔積水(malignant pleural effusion, MPE)中建立罕見DCTN1–ALK內生性細胞模型,以深入解析其分子特徵與治療表現型。 本實驗成功自ALK陽性肺腺癌病人之惡性胸腔積水中分離並建立了新型病人衍生細胞株(patient-derived cell line),命名為 CS146。。實驗以H2228(EML4-ALK v3陽性)與A549(ALK陰性)作為對照細胞株,透過西方墨點法(Western blot)偵測ALK蛋白表現,並利用次世代定序(next-generation sequencing, NGS)鑑定融合斷點;最後採用CCK-8 細胞增殖與代謝活性試驗(cell counting kit-8 assay),評估 Crizotinib、Alectinib 及 Lorlatinib(0–20 μM,作用 72 小時)對該細胞之增殖抑制效果。 結果顯示,此惡性胸腔積水衍生細胞株表達高分子量之 ALK 融合蛋白(>175 kDa),其明顯異於 H2228 的典型條帶(~100 kDa);透過NGS 進一步證實,該細胞攜帶 DCTN1-ALK融合基因,此為國內外首例由胸水成功衍生之內生性肺癌細胞模型。CCK-8 藥敏試驗結果指出,該模型對三款不同世代 ALK-TKIs 之藥物敏感程度皆與標準株 H2228 存在極顯著的統計學差異,提示 DCTN1-ALK 具備獨特的標靶藥敏特性。 我們首創自惡性胸腔積水成功建立 DCTN1-ALK內生性肺癌細胞株,不僅為探討罕見 ALK 融合蛋白之結構功能關係與訊號傳導異質性奠定關鍵基石,亦為後續長期藥敏篩選與適應性抗藥機制研究提供了核心評估平台。期望未來結合本中心持續擴充之胸水衍生腫瘤模型庫,優化肺腺癌病人之臨床預後。
Lung cancer remains the leading cause of cancer-related mortality globally and in Taiwan, with lung adenocarcinoma representing the predominant pathological subtype of non-small cell lung cancer (NSCLC). Although EGFR and KRAS mutations, along with ALK gene rearrangements, are well-established key oncogenic driver genes and therapeutic targets, and multi-generation ALK tyrosine kinase inhibitors (ALK–TKIs) have significantly improved patient outcomes, distinct fusion partners (e.g., EML4 and DCTN1) frequently shape unique protein structures and modulate drug sensitivity. This study aimed to establish a rare DCTN1–ALK endogenous cell model derived from malignant pleural effusion (MPE) to elucidate its molecular characteristics and therapeutic phenotypes. A novel cell line was successfully isolated and established from the MPE of a patient with ALK-positive lung adenocarcinoma. H2228 (EML4–ALK v3-positive) and A549 (ALK-negative) cells were utilized as control groups. ALK protein expression was detected via Western blot analysis, and the fusion breakpoint was identified using next-generation sequencing (NGS). Finally, CCK-8 cell proliferation assays were performed to evaluate the anti-proliferative efficacy of Crizotinib, Alectinib, and Lorlatinib (0–20 μM, 72-hour treatment) on the established cells. Molecular characterization revealed that this MPE-derived cell line expressed a high-molecular-weight ALK protein (>175 kDa), which was distinctly different from that of H2228 (~100 kDa). NGS further confirmed that these cells harbored the DCTN1–ALK (D26:A20) fusion gene, representing the first MPE-derived endogenous model reported both domestically and internationally. Moreover, CCK-8 drug sensitivity assays demonstrated that the drug responsiveness and dose-response profiles of this model toward the three generations of ALK–TKIs exhibited statistically highly significant differences compared to the standard reference strain H2228, highlighting the unique targeted drug sensitivity trajectory of the DCTN1–ALK variant. This study marks the first successful establishment of an MPE-derived DCTN1–ALK (D26:A20) endogenous lung cancer cell line. This model not only lays a cornerstone for investigating the structure-function relationships and signaling heterogeneity of rare ALK fusion proteins but also serves as a critical evaluation platform for subsequent drug screening and resistance mechanism studies. Our findings will contribute to the evaluation of precision medicine strategies for rare ALK variants. In the future, integration with a continuously expanding depository of MPE-derived tumor models is expected to comprehensively optimize the clinical prognosis of patients with ALK-positive lung adenocarcinoma.
Subjects
非小細胞肺癌
肺腺癌
惡性胸腔積水
ALK 融合基因
Non-Small Cell Lung Cancer
Adenocarcinoma
Malignant pleural effusion
DCTN1–ALK
ALK fusion gene
Type
thesis
File(s)
No Thumbnail Available
Name
115CSMU0534005-001.pdf
Size
1.62 MB
Format
Adobe PDF
Checksum
(MD5):e086a04f63be72b04ad250f80bc8dc3c